By Turna Ray

This article was originally posted on Oct. 30.

Even Google-backed 23andMe isn't shielded from the economic crisis.

The Mountain View, Calif.-based direct-to-consumer genomics firm has had a round of layoffs that it said were necessary to remain in business in a difficult economic climate. With competitor Decode Genetics also cutting back, Navigenics proceeding cautiously, and TruGenetics in a holding pattern as it seeks funding, times are tough for DTC consumer genomics firms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.